Menu
X

Miracle Unfolds: Zhejiang University Hospital’s Custom CRISPR/Cas9 Gene Editing + CAR-T Cell Therapy Rebirths Patients

๐ŸŒŸ Miracle Unfolds: Zhejiang University Hospital’s Custom CRISPR/Cas9 Gene Editing + CAR-T Cell Therapy Rebirths Patients ๐ŸŒŸ

ย 

๐Ÿ‘จโ€๐Ÿ‘งโ€๐Ÿ‘ฆ (โ€œI want to live to see my child go to university!โ€)๐Ÿ‘จโ€๐Ÿ‘งโ€๐Ÿ‘ฆ

CAR-T Cell Therapy Patient

CAR-T Cell Therapy Patient

ย 
๐ŸŽ“ This heartfelt cry came from Mr. Sun, a 40-year-old patient from Guangzhou, who faced the formidable challenge of diffuse large B-cell lymphoma, a common adult lymphoma type.
ย 

๐Ÿ”ฌ14 rounds of chemotherapy, 20 rounds of radiotherapy, total gastrectomy… For two years,

Mr. Sun sought treatment nationwide, endured endless suffering, yet couldn’t defeat the chameleon of the tumor world โ€“ diffuse large B-cell lymphoma.
โ€œIt’s tough. Prepare yourself mentally.โ€ โ€œI want to live to see my child go to university.โ€
ย 

๐Ÿ‹Seeking a glimmer of hope, he turned to Zhejiang University Hospital in Hangzhou. This time, the doctors said, “Let’s give it a try together.”

Multiple abdominal lymphoma lesions invading the intestinal wall, multiple rounds of chemo couldn’t stop the lymphoma from spreading everywhere. Intestinal wall invasion by lymphoma is a relative contraindication for CAR-T therapy, as it can lead to intestinal perforation, so he was no longer suitable for traditional CAR-T cell therapy.
ย 
๐ŸŒฟProf. Liu Mingyao’s team and Prof. Huang He’s team used the Nobel Prize-winning CRISPR/Cas9 gene editing technology to precisely knock out the PD1 site in T lymphocytes and insert the targeted CD19 CAR molecule for tumor cells, creating a brand-new non-viral targeted integrated CAR-T cell (PD1-19bbz), and successfully completed Phase I clinical trials in humans for the first time, verifying the safety and efficacy of the new CAR-T cells.
ย 

๐Ÿ’ชThe brand-new PD1-19bbz CAR-T cells, with a low risk of cytokine storms and other complications, gave Mr. Sun a new lease on life.

ย 
๐Ÿ‘‘Mr. Sun received PD1-19bbz CAR-T cell infusion and returned. Fourteen days after CAR-T cell return, all indicators were normal. After evaluation, he was discharged. One month after the return, PET-CT evaluation showed that the large mass of tumor invading the intestinal mucosa in the original abdominal cavity had completely disappeared.
ย 

๐ŸธToday, Mr. Sun has been disease-free for over 2 years.

In a recent follow-up, all of Sun’s examination results were normal, his weight had increased significantly compared to before his illness, and his complexion looked much healthier. “After cell therapy, my body suddenly felt normal again. My friends and family all say I’ve miraculously recovered. Now in my spare time, I even play badminton, completely restoring my pre-illness lifestyle.”
ย 
Tsinghua University

Tsinghua University

๐ŸŽจTwo years later, in the summer of 2022, Mr. Sun shared good news with the medical staff in Hangzhou: his child has been accepted to the School of Arts at Tsinghua University!
ย 
๐ŸŽ‰To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!
ย 

WhatsApp: +8613717959070

ย 
๐ŸŒฟ #MiracleRebirth #CRISPR #CARTCellTherapy #ZhejiangUniversity #TsinghuaUniversity #MedicalBreakthroughs #CancerTreatmentย 

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

ยฉ Copyright 2023 Advanced Medicine In China. All rights reserved.